<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04769414</url>
  </required_header>
  <id_info>
    <org_study_id>352</org_study_id>
    <nct_id>NCT04769414</nct_id>
  </id_info>
  <brief_title>Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)</brief_title>
  <official_title>A Phase II Trial of Flouro-Gem as a First Line Treatment of Metastatic Adenocarcinoma of the Pancreas (GEFLUPAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators designed a treatment regimen including the most active&#xD;
      agents in pancreatic cancer which are gemcitabine and fluorouracil to be tested as a first&#xD;
      line treatment. This regimen is expected to be less toxic than FOLFIRINOX and aiming at&#xD;
      better outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metastatic cancer pancreas has been a challenge for oncologists over the years. It is a&#xD;
      disease of limited survival and a very poor response to treatment. The median overall&#xD;
      survival at five years is expected to be between 4-6% only. Adenocarcinoma is the most common&#xD;
      type of pancreatic cancer. It is the tenth most common adult solid malignancy. Most of the&#xD;
      new therapeutic modalities has proven to be non-beneficial in this disease including targeted&#xD;
      and immunotherapy.&#xD;
&#xD;
      For many years, the first line of treatment for pancreatic cancer was gemcitabine either&#xD;
      alone or in combinations. Recently, FOLFIRINOX has become the standard of care due to its&#xD;
      overall survival benefit. However, it is a small benefit on the expense of great toxicity.&#xD;
&#xD;
      Patients with metastatic cancer pancreas are recruited to receive the test regimen. Baseline&#xD;
      evaluation will be done either by CT scan or PET/CT. re-evaluation will be repeated after 3&#xD;
      months of treatment and at end of 6 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 20, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>6 months from enrollment</time_frame>
    <description>describes according to RECIST criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>6 months from chemotherapy</time_frame>
    <description>Describes according to CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>One year from start of enrollment</time_frame>
    <description>The time interval between the date of metastasis to the date of next disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>One year from start of enrollment</time_frame>
    <description>The time interval between the date of diagnosis till the date of death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cancer of Pancreas</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the test protocol Gem-5FU on biweekly basis for 6 months with interim evaluation&#xD;
Doses as follows:&#xD;
Gemcitabine 1000 mg/m2, infusion over 30 min, D1, D15 Leucovorin 400 mg/m2 infusion over 30 min , D1, D15 5FU 400 mg/m2 I.V. shot D1, D15 5FU 2000 mg/m2 infusion over 46 hours D1 , D15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine fluorouracil</intervention_name>
    <description>chemotherapy protocol given as:&#xD;
Gemcitabine 1000mg/m2 IV short infusion&#xD;
Leucovorin 400 mg/m2 IV short infusion&#xD;
Flourouracil 400 mg/m2 direct IV shot&#xD;
Flourouracil 2000 mg/m2 contineous infusion over 46 hours&#xD;
The whole regimen will be repeated bi-weekly</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathological evidence of adenocarcinoma of the pancreas&#xD;
&#xD;
          -  Radiological proof of metastatic disease as defined by AJCC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with poor performance status (ECOG 4)&#xD;
&#xD;
          -  patients with organ dysfunction defined as: creatinine more than 1.6 mg/dl or&#xD;
             bilirubin more than 3 mg/dl&#xD;
&#xD;
          -  patients with end stage renal disease who are under regular dialysis&#xD;
&#xD;
          -  other histologies of pancreatic cancer&#xD;
&#xD;
          -  irresectable pancreatic cancer if not metatatic&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Sohaib, PhD</last_name>
    <phone>+201060406063</phone>
    <email>ahmed.sohaib@med.menofia.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amira Hegazy, PhD</last_name>
    <phone>+201090432337</phone>
    <email>amirahegazy28@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Menoufia University, Faculty of medicine</name>
      <address>
        <city>Shebin Elkom</city>
        <state>Menoufia</state>
        <zip>32511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Sohaib, PhD</last_name>
      <phone>01060406063</phone>
      <email>dr.ahmed.sohaib@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Amira Hegazy, PhD</last_name>
      <phone>01090432337</phone>
      <email>amirahegazy28@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Reham Ahmed, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.</citation>
    <PMID>21561347</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 21, 2021</last_update_submitted>
  <last_update_submitted_qc>February 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>Ahmed Sohaib</investigator_full_name>
    <investigator_title>Lecturer of Clinical oncology</investigator_title>
  </responsible_party>
  <keyword>pancreas</keyword>
  <keyword>cancer</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>metastatic</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>flourouracil</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>first line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD can be shared with other investigators upon personal contact with the PI of the study and after publishing the primary results. The investigators of this study are to be submitted as co-investigators in any other studies using the data of this study.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>After publishing the primary results of the study, expected to be by January 2023</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

